Perez-Perez, Maria-Jesus, Delang, Leen, Ng, Lisa FP 
ORCID: 0000-0003-4071-5222 and Priego, Eva-Maria
(2019)
Chikungunya virus drug discovery: still a long way to go?
Expert Opinion on Drug Discovery, 14 (9).
pp. 855-866.
Abstract
<b>Introduction</b>: Chikungunya virus (CHIKV) is the etiological agent of a (re)emerging arbovirus infection, chikungunya fever (CHIKF), that represents a serious health problem worldwide for which no antivirals are available. <b>Areas covered</b>: This review covers the efforts performed so far to identify and optimize small molecules that could be useful as antivirals for CHIKV infection, including drug repositioning, phenotypic screening, target-based screening, and structure-based design. This is accompanied by a brief presentation of the replicative cycle of the virus and the role of the viral proteins in CHIKV replication. <b>Expert opinion</b>: In the last decade, and particularly since CHIKV reached the Americas, significant efforts have been made to identify compounds that effectively inhibit CHIKV replication. Unfortunately, these efforts have not led to a clinical candidate. For the years to come, more basic research is required to allow a better understanding of the interplay of the viral proteins among them and with cellular components. Structural information is missing for most of the targets so that structure-based drug design, a strategy that has provided good results in other antiviral fields, has been scarcely applied to this alphavirus.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Chikungunya virus, drug repurposing, phenotypic screening, structure-based drug design, target-based assays |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 06 Feb 2020 10:04 |
| Last Modified: | 19 Jan 2023 00:04 |
| DOI: | 10.1080/17460441.2019.1629413 |
| Open Access URL: | https://digital.csic.es/bitstream/10261/190685/1/E... |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3073751 |
Dimensions
Dimensions
